Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2001

View Archived Issues

Pfizer succeeds in enhancing CNS penetration of a potent and selective NK1 antagonist

Forest licenses NMDA antagonist from Merz

AEterna's Neovastat demonstrates safety and dose-related activity in prostate cancer trial

TAU, Elan and AHP to codevelop immunological approaches to Alzheimer's disease

Genetronics and Chiron sign second agreement relating to electroporation

Bradykinin B2 antagonists with anticancer activity

Ertapenem: in vitro activity against anaerobic isolates from patients

Important Gram-positive and Gram-negative bacteria tested for susceptibility to BMS-284756

PSK evaluated in clinical trials as adjuvant immunochemotherapy in colorectal cancer

Peregrine's TNT treatment shows positive results in phase I/II trial

U.S. university researchers design potent and selective human MC4 receptor agonist

Pharmacological profile of KF-19418 suggests potential in human alopecia

Organon Teknika's diagnostic unit acquired by bioMerieux

Vernalis and Alcon enter glaucoma alliance

High-dose coenzyme Q10 proves safe and effective in migraine prevention

Patient enrollment complete in VALIANT trial of Diovan for long-term survival following MI

NewBiotics presents data supporting antibiotic that exploits the resistance enzyme

Dianon Systems to acquire UroCor

Schering AG creates new company

Human fibroblast growth factor gene and use in cirrhosis and cancer

Merck KGaA presents new modified EPO forms

Antibacterial and antiprotozoal erythromycin-based compounds

Novel compounds synthesized at Fujimoto useful for hyperlipidemia

Metalloprotease inhibitors with therapeutic potential discovered at Roche

Treatments for prostaglandin-mediated diseases in development at Merck Frosst

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...